Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7263221 | 1.00 | RAB9A (0.35) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL13983475 | 1.00 | RAB9A (0.35) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL8374251 | 0.86 | ALDH1A1 (0.39) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL8979396 | 0.86 | ALDH1A1 (0.39) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL9044976 | 0.86 | ALDH1A1 (0.39) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL29198506 | 0.86 | ALDH1A1 (0.39) | RAB9AMEN1KMT2ASLC6A3TSHR | |
| SCHEMBL2380756 | 0.83 | SLC6A3 (0.43) | MEN1KMT2ASLC6A3TSHR | |
| SCHEMBL1829324 | 0.83 | SLC6A3 (0.43) | MEN1KMT2ASLC6A3TSHR | |
| SCHEMBL2380760 | 0.83 | SLC6A3 (0.43) | MEN1KMT2ASLC6A3TSHR | |
| SCHEMBL4735100 | 0.83 | SLC6A3 (0.43) | MEN1KMT2ASLC6A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329582-A1 | SMALL MOLECULE COMPOUNDS SELECTIVE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-11-19 | — | — | US | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157657-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6653296-B1 | 2-phosphonomethoxypropyl derivatives of purine and pyrimidine bases | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-11-25 | — | — | US | disclosed |
| EP-0897917-A1 | Compounds for use in the preparation of antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1999-02-24 | — | — | EP | disclosed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | DCTD, SAMHD1, SLC28A1 | RAB9A 2508/4885MEN1 3255/4885KMT2A 1287/4885 |
| US-20150329582-A1 | SMALL MOLECULE COMPOUNDS SELECTIVE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS | MANBA, DDOST, PGLS | RAB9A 205/4885MEN1 372/4885KMT2A 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.